CSX Corporation (NASDAQ:CSX) recently ticked higher on weak volume. About 3.7 million contracts were traded on 21-Nov-17 compared to daily average volume of 5.67 million shares. The first sale was made at $49.76 but later the stock became weaker, and closed with a gain of 1.03%. It was last traded at $50.22 apiece. CSX Corporation is maintained at an average outperform rating by 27 stock analysts, and there are at least 1.87% of shares outstanding that are currently legally short sold. The shares went down by -7.21% in value last month. Year-to-date it jumped 39.77%. Analysts are turning out to be more optimistic than before, with 18 of analysts who cover CSX Corporation (NASDAQ:CSX) advice adding it to buy candidate list. Wall Street experts also assign a $57.92 price target on CSX Corporation, pointing towards a 15.33% rally from current levels. The stock is trading for about -9.48% less than its 52-week high. CSX Corporation (CSX) remained unsuccessful in beating the consensus-estimated $0.51 as it actually earned $0.51 per share in its last reported financial results. Revenue, on the other hand, scored -5.49% growth from the previous quarter, coming up with $2.77 billion.  This company shares (CSX) so far managed to recover 47.66% since collapsing to its 52-week low. Over a month, it has seen its stock price volatility to stay at 1.95% while shortening the period to a week, volatility was 2.23%. The share price has yet to cross its 20 days moving average, floating at a distance of -1.49% and sits -3.75% lower versus its 50 days moving average. When looking at the past five sessions, the stock returned 1.66% gains and is down by -1.2% compared with its 200-day moving average of $51.98. Also, CSX Corporation (CSX) needs to expand a 45.1% increase it experienced over the past twelve months. As regular trading ended, BioCryst Pharmaceuticals, Inc. (BCRX) stock brought in a $0.02 rise to $4.53. The day started at a price of $4.53 but then traded as high as $4.64 before giving part of the gains back. As for this week, analysts appear content to stick with their neutral outlook with the consensus call at 2.2. BioCryst Pharmaceuticals, Inc. is given 2 buy-equivalent recommendations, 0 sells and 2 holds. The company shares sank -51.03% from their peak of $9.25 and now has a $456.62 million market value of equity. BCRX’s mean recommendation on Reuter’s scale presents no change from 2.2 thirty days ago to 2.2 now, which indicates a hold consensus from the analyst community. They see BioCryst Pharmaceuticals, Inc. (BCRX) price hitting a mean target of $8.56 a share, meaning the stock still has potential that could lift the price another 88.96% Also, the recent close suggests the stock is underpriced by 164.9% compared to the most bullish target. The company had seen its current volume reaching at 0.53 million shares in the last trade. That compares with the recent volume average of 1.66 million. At the close of regular trading, its last week’s stock price volatility was 4.68% which for the month reaches 4.35%. BioCryst Pharmaceuticals, Inc. dipped to as low as $4.49 throughout the day and has returned -28.44% in this year. At one point in the past year, the shares traded as low as $3.95 but has recovered 14.68% since then.